The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).
The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...
Studies have shown that using liquid-based cytology (LBC) under the Sydney system can achieve high diagnostic accuracy, with sensitivity and specificity rates exceeding 98%[2]. This advancement is ...
A DNA methylation test is one of several noninvasive biomarkers test under investigation for the early diagnosis of bladder cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback